20/20 BioResponse

20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development. By leveraging this expertise and combining it with advanced machine learning and data analytics, new tests are being released which substantially improve the accuracy of biomarker blood tests for the early detection of cancers. This unique approach, being pioneered by 20/20, results in affordable, highly accurate cancer blood tests.